Navigation Links
Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
Date:8/24/2009

HOERSHOLM, Denmark, August 24 /PRNewswire/ --

- Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders

- Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery

- Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

The alliance will use Santaris Pharma A/S' proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets. Shire will be responsible for the selection of appropriate drug candidates, as well as further development and commercialization of products arising from the alliance.

Under the terms of the agreement Santaris Pharma A/S will receive initial early stage payments of US$6.5 million covering technology access, exclusivity for three pre-defined targets and initial discovery funding, and an additional early stage payment of US$13.5 million upon successful completio
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
2. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
3. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
4. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
5. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
8. Pre-Owned Prices on Premium Pharmaceutical Equipment
9. Laureate Pharma Elects New Board Member
10. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
11. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... Raptor Pharmaceuticals Corp.,(OTC Bulletin Board: RPTP), today announced ... development subsidiary, will,present at the 2008 BIO International Convention ... Convention Center in San Diego, CA., Mr. Daley,s ... 2008 at 1:15p.m. (PT) in room 4 of the ...
... Skeletal Managed Care Organization Takes Prominent Position and ... at AHIP Conference, WEST SENECA, N.Y., June 11 ... announced their plans to,create a high-profile presence at a ... in San Francisco, Wednesday, June,18 to Friday, June 20, ...
... of Blockages in ... the Femoropopliteal Artery, VANCOUVER, ... TSX: ANP), a global specialty pharmaceutical and,medical device company, today ... results from the registry arm of a,clinical study measuring the ...
Cached Biology Technology:Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 2Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 3Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 4Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June 2Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 2Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 3Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 4Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 5
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Apple introduced the fingerprint reading feature with the iPhone ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... BioPharma, Inc. today announced that it has begun oral dosing ... ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside ... RSV infection. It is the only known nucleoside analog ... ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV ...
... uses pedometers to monitor how much people move throughout the ... a particular problem for office workers, and helping participants drop ... minutes a day, the fact that they,re sitting and not ... the day is in and of itself detrimental to their ...
... undergoing hemodialysis are known to be highly susceptible to heart ... why. New research findings published in the Journal ... are not removed by hemodialysis, increase heart attack risk. The ... an oral adsorbent called "AST-120." ...
Cached Biology News:Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection 2Study: Pedometer program helps motivate participants to sit less, move more 2
... This high pressure gradient system ... piston pumps, each providing a flow rate in ... dual wavelength detector for added flexibility. System ... data processing software and interface unit, CE 4900., ...
... The excellent isocratic refractive index chromatography system, uses ... CE 4700. Data processing is provided by ... is by the high pressure CE 4100 dual ... be supplied. The system can be ...
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
...
Biology Products: